Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

Sjogren's Disease Clinical Trial

Official title:
Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®) on the surface of the eye and tear film (a film that coats the eye which is made up of oil and water).

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02322528
Study type	Interventional
Source	University of Rochester
Contact
Status	Completed
Phase	N/A
Start date	April 2014
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02148497` - Multi-Colored Placido Disk Viability	N/A
Completed	`NCT02358213` - Evaluation of the Reproducibility Inter-observer of the Ultrasound Anomalies of the Salivary Glands in Sjogren's Disease	N/A
Completed	`NCT00740948` - Tolerance and Efficacy of Rituximab in Sjogren's Disease	Phase 2/Phase 3
Not yet recruiting	`NCT06392711` - Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia	Phase 1
Completed	`NCT01234623` - Cord Blood Serum in the Treatment of Ocular Surface Diseases	Phase 1